Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Axcella Health Inc.AXLA · Entity 116059 | SVP & Chief Business Officer | December 18, 2019 | December 20, 2019 |
| Karyopharm Therapeutics Inc.KPTI · Entity 781 | SVP, Chief Business Officer | February 28, 2023 | March 02, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Axcella Health Inc.
Report date December 18, 2019 · Filed December 20, 2019
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.40 · Expires 2029-12-18 | Direct | 43,000 |
Reported balance
After 2019-12-18 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2019-12-18 · Grant · Acquired 43,000 · Balance 43,000 F1: 25% of this option shall vest and become exercisable on December 18, 2020, with the remainder to vest in 12 equal quarterly installments thereafter. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of this option shall vest and become exercisable on December 18, 2020, with the remainder to vest in 12 equal quarterly installments thereafter.
Karyopharm Therapeutics Inc.
Report date February 28, 2023 · Filed March 02, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 134,670 |
Reported balance
After 2023-02-28 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2023-02-28 · Grant · Acquired 60,000 · Balance 134,670 F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024. F2: Includes 2,147 shares and 1,977 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on April 30, 2022 and October 31, 2022, respectively. |
| Common StockSEC Table I · non-derivative | Direct | 128,313 |
Reported balance
After 2023-03-01 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2023-03-01 · Sale · Disposed 6,357 · Balance 128,313 F3: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024.
F2: Includes 2,147 shares and 1,977 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on April 30, 2022 and October 31, 2022, respectively.
F3: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 01, 2023 Filed Mar 2, 2023 22:36 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 6,357 | $3.03 | $19,256.62 |
DisclosureSEC source: 0001209191-23-014869 · doc4.xml · nonDerivative · entry 2 Mitchener Stephen · CIK 0001774519 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 128,313 F3 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. Read SEC document |
| February 28, 2023 Filed Mar 2, 2023 22:36 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 60,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-014869 · doc4.xml · nonDerivative · entry 1 Mitchener Stephen · CIK 0001774519 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 134,670 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan. RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in three equal annual installments beginning February 28, 2024. F2 · balance_after: Includes 2,147 shares and 1,977 shares acquired under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on April 30, 2022 and October 31, 2022, respectively. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 01:03 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 30,000 | $0.00 Strike: $5.06 | $0.00 |
DisclosureSEC source: 0001209191-22-048397 · doc4.xml · derivative · entry 2 Mitchener Stephen · CIK 0001774519 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2032-08-30 F2 · derivative.exercise_date: This option was granted on August 31, 2022 pursuant to the Plan. The shares underlying this option vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024. Read SEC document |
| August 31, 2022 Filed Sep 2, 2022 01:03 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-048397 · doc4.xml · nonDerivative · entry 1 Mitchener Stephen · CIK 0001774519 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,546 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2022 Equity Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest as to 50% of the shares on August 31, 2023, with the remaining 50% vesting on August 31, 2024. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 20:15 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantStock Option (right to buy) · Derivative | 59,400 | $0.00 Strike: $10.33 | $0.00 |
DisclosureSEC source: 0001209191-22-014623 · doc4.xml · derivative · entry 2 Mitchener Stephen · CIK 0001774519 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,400 Underlying: Common Stock · 59,400 shares Expires 2032-02-27 F2 · derivative.exercise_date: This option was granted on February 28, 2022 pursuant to the Plan. The shares underlying this option vest as to 25% of the shares on February 28, 2023, with the remaining 75% vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 20:15 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | GrantCommon Stock | 47,250 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-014623 · doc4.xml · nonDerivative · entry 1 Mitchener Stephen · CIK 0001774519 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,546 F1 · shares: Represents the award of restricted stock units ("RSUs") pursuant to the Karyopharm Therapeutics Inc. 2013 Stock Incentive Plan (the "Plan"). RSUs convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. The RSUs vest in four equal annual installments beginning February 28, 2023. Read SEC document |
| December 02, 2021 Filed Dec 3, 2021 23:17 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 499 | $6.69 | $3,338.31 |
DisclosureSEC source: 0001209191-21-067954 · doc4.xml · nonDerivative · entry 1 Mitchener Stephen · CIK 0001774519 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,296 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary sale by the reporting person. F2 · balance_after: Includes 1,323 shares acquired by the reporting person under the Karyopharm Therapeutics Inc. 2013 Employee Stock Purchase Plan on October 31, 2021. Read SEC document |
| June 02, 2021 Filed Jun 3, 2021 20:06 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | SaleCommon Stock | 528 | $9.29 | $4,905.12 |
DisclosureSEC source: 0000899243-21-021767 · doc4.xml · nonDerivative · entry 1 Mitchener Stephen · CIK 0001774519 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,472 F1 · kind: This transaction was a broker-assisted sale of shares to satisfy the payment of withholding tax liability incurred upon the vesting of restricted stock units and does not represent a discretionary trade by the reporting person. Read SEC document |
| May 30, 2021 Filed Jun 1, 2021 20:05 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionRestricted Stock Units · Derivative | 1,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-021292 · doc4.xml · derivative · entry 2 Mitchener Stephen · CIK 0001774519 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,500 Underlying: Common Stock · 1,500 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units ("RSUs") convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F3 · derivative.exercise_date: On November 30, 2020, the reporting person was granted 3,000 RSUs, which vested as to 50% of the shares on May 30, 2021, with the remaining 50% vesting on November 30, 2021. 1,500 of the RSUs vested on May 30, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. F3 · derivative.expiration_date: On November 30, 2020, the reporting person was granted 3,000 RSUs, which vested as to 50% of the shares on May 30, 2021, with the remaining 50% vesting on November 30, 2021. 1,500 of the RSUs vested on May 30, 2021. Vested shares will be delivered to the reporting person as soon as practicable following the vesting date, but in any event within 30 days of such date. Read SEC document |
| May 30, 2021 Filed Jun 1, 2021 20:05 UTC | Karyopharm Therapeutics Inc. KPTI · Entity 781 | Exercise / conversionCommon Stock | 1,500 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-21-021292 · doc4.xml · nonDerivative · entry 1 Mitchener Stephen · CIK 0001774519 · SVP, Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units ("RSUs") convert into Karyopharm Therapeutics Inc. common stock on a one-for-one basis. F2 · balance_after: The reporting person has reported a prior award of 3,000 RSUs (described in footnote 3 below) in Table II of Form 4. The total reported in Column 5 includes 1,500 RSUs previously reported in Table II and 1,500 shares of common stock. Read SEC document |
| December 18, 2019 Filed Dec 20, 2019 20:04 UTC | Axcella Health Inc. AXLA · Entity 116059 | GrantStock Option (Right to Buy) · Derivative | 43,000 | $0.00 Strike: $3.40 | $0.00 |
DisclosureSEC source: 0001104659-19-075210 · a4.xml · derivative · entry 1 Mitchener Stephen · CIK 0001774519 · SVP & Chief Business Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,000 Underlying: Common Stock · 43,000 shares Expires 2029-12-18 F1 · derivative.exercise_date: 25% of this option shall vest and become exercisable on December 18, 2020, with the remainder to vest in 12 equal quarterly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.